Skip to nav Skip to content

Clinical Trial Search

306 Clinical Trials Found

Clinical Trial 21997

Adaptive Therapy of Vismodegib in Advanced Basal Cell Carcinoma
Disease Site: Other Skin
PI: Eroglu, Zeynep

Clinical Trial 22002

A Multicenter Open-Label Study of RMC-6236 in Patients with Advanced Solid Tumors Harboring Specific Mutations in RAS
Disease Site: Any Site, Liver, Lung, Other Digestive Organ, Pancreas, Small Intestine, Stomach
PI: Kim, Dae Won

Clinical Trial 22003

A Phase II Randomized Study of Sipuleucel-T with or without Continuing New Hormonal Agents (NHA) in Metastatic Prostate Cancer with PSA Progression while on NHA and LHRH Analog
Disease Site: Prostate
PI: Zhang, Jingsong

Clinical Trial 22071

Melanoma Margins Trial (MelMarT-II): A Phase III, multi-centre, multi-national randomised control trial investigating 1cm v 2cm wide excision margins for primary cutaneous melanoma
Disease Site: Other
PI: Zager, Jonathan

Clinical Trial 22095

A Phase 2 study of Canakinumab in patients with Myelofibrosis
Disease Site: Myeloid and Monocytic Leukemia
PI: Kuykendall, Andrew

Clinical Trial 22100

Disease Site: Multiple Myeloma
PI: Grajales-Cruz, Ariel

Clinical Trial 22134

AbatacepT foR ImmUne checkpoint inhibitor associated Myocarditis (ATRIUM): A Phase 3, Investigator-Initiated, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Abatacept Compared to Placebo in Hospitalized Participants with Immune Checkpoint Inhibitor Associated Myocarditis
Disease Site: Other
PI: Alomar, Mohammed

Clinical Trial 20773

Neoadjuvant Lenvatinib Plus Pembrolizumab in Resectable Merkel Cell Carcinoma
Disease Site: Merkel cell carcinoma, Other Skin
PI: Brohl, Andrew

Clinical Trial 20056

Phase II Clinical Trial of Green Tea Catechins in Men on Active Surveillance (AS)
Disease Site: Prostate
PI: Kumar, Nagi

Clinical Trial 21056

Disease Site: Lymphoid Leukemia
PI: Sandoval-Sus, Jose

Clinical Trial 20938

A Randomized Phase II Trial of Adjuvant Pembrolizumab Versus Observation Following Curative Resection for Stage I Non-Small Cell Lung Cancer (NSCLC) with Primary Tumors Between 1-4 cm
Disease Site: Lung
PI: Chiappori, Alberto

Clinical Trial 20494

A Phase II Study of High Dose Bolus IL2 in Combination with Low Dose Ipilimumab Followed Sequentially by Nivolumab in Patients with Inoperable Stage III or Stage IV Melanoma Who Have Failed Prior Anti-PD1 Immunotherapy
Disease Site: Melanoma, skin
PI: Tarhini, Ahmad